NIH R01 · 2025
The liver is a frequent site of metastasis for several cancers and when this occurs, it is associated with poor response to immunotherapy. Liver-directed radiotherapy (RT) is a non-traditional immune modulating therapy that improves immune checkpoint blockade (ICB, αPD-1 or αPD-1/αCTLA-4) mediated control of liver metastasis and non-irradiated abscopal tumors. Unfortunately, enhanced tumor control following liver-directed radiotherapy and ICB is often short-lived for irradiated tumors and unpredictable for non-irradiated tumors. Thus, novel immunotherapeutic approaches that can stimulate antitumor immunity in the liver have the potential to boost liver-directed RT plus ICB mediated control…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.